TMCnet News
Altasciences Conducts Alcohol Drug-Drug Interaction Study for Amygdala Neurosciences Inc.Vince & Associates Clinical Research, an Altasciences company, announced today that they are working with Amygdala Neurosciences Inc. to conduct a Phase 1b, proof-of-concept, dose-ranging study to evaluate the safety of the co-administration of ascending doses of ANS (News - Alert)-6637 and ethanol in healthy male alcohol drinkers. The potential clinical indication for ANS-6637 is the treatment of substance abuse, including alcohol and cocaine dependence. Therefore, Amygdala is evaluating the interaction between ANS-6637 and alcohol. Vince & Associates will assess the safety and tolerability of ANS-6637 in combination with an alcohol consumption regimen expected to cause intoxication. "Vince & Associates' decades of experience, highly qualified team and large database of volunteers made them the obvious choice for our Phase 1b study." said Peter M. Strumph, Chief Executive Officer at Amygdala Neurosciences, Inc. Vince & Associates is highly successful in conducting complex clinical trials and is able to quickly recruit special populations, such as healthy, mild to moderate alcohol drinkers, due to their extensive volunteer database. In addition, Vince & Associates' physicians offer years of experience in enrolling and qualifying study volunteers according to strict Inclusion and Excluson criteria. The rapid start up and enrollment of qualified volunteers ensures sponsors receive quality data earlier, so that they can make quicker go/no-go decisions on their important drug development programs. "Vince & Associates appreciates the opportunity to work with the professional team at Amygdala and is excited to be involved in developing drug candidates for addiction disorders," stated Dr. Brad Vince, CEO and Medical Director.
About Altasciences
View source version on businesswire.com: http://www.businesswire.com/news/home/20171018005151/en/ |
